New drug trial offers hope for bulging, painful eyes caused by thyroid disease
NCT ID NCT07152340
Summary
This study is testing a new drug called IBI311 against the standard steroid treatment for active, moderate-to-severe Thyroid Eye Disease (TAO). It will enroll 64 adults who have not yet received steroid treatment for their eye condition. The main goal is to see which treatment is better and safer at reducing eye bulging (proptosis), inflammation, and double vision.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THYROID ASSOCIATED OPHTHALMOPATHIES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Changzheng Hospital
RECRUITINGChanghua, Shanghai Municipality, 200003, China
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
-
Shanghai Changzheng Hospital
NOT_YET_RECRUITINGShanghai, Shanghai Municipality, 200003, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.